Table 2 Effect of subgroups
From: Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis
Subgroup | Studies | SEN (95% CI) | SPE (95% CI) | DOR (95% CI) | I2(%) | P | |
|---|---|---|---|---|---|---|---|
Pathological types of patients | Adenocarcinoma + other types | 6 | 0.652 (0.618 to 0.685) | 0.903 (0.877 to 0.925) | 27.291 (11.011 to 67.640) | 77.10 | 0.001 |
Unclear | 2 | 0.437 (0.380 to 0.496) | 0.950 (0.923 to 0.970) | 14.524 (8.547 to 24.681) | 0.00 | 0.817 | |
Control | Uterine benign diseases + healthy | 4 | 0.500 (0.449 to 0.551) | 0.917 (0.889 to 0.940) | 22.555 (5.473 to 92.943) | 80.10 | 0.002 |
Healthy | 4 | 0.646 (0.609 to 0.682) | 0.923 (0.896 to 0.945) | 23.426 (15.767 to 34.806) | 3.50 | 0.375 | |
Total | 8 | 0.594 (0.564 to 0.623) | 0.920 (0.901 to 0.936) | 20.816 (11.434 to 37.896) | 68.40 | 0.0024 |